Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2022-12-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于调整公司组织架构的公告
Board/Management Information Classification · 95% confidence The document is an announcement from a company about adjustments to its organizational structure, approved by the board of directors. It discusses changes in the company's internal management and organizational setup, which aligns with information about board or management changes. There is no financial data, no mention of financial results, no voting results, no legal proceedings, or other report types. The document length is short and it is a direct announcement, not a report or presentation. Therefore, the most appropriate classification is Board/Management Information (MANG).
2022-12-07 Chinese
关于公司及子公司向银行申请综合授信及贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yunnan Watson Biotechnology Co., Ltd. regarding the company's and its subsidiaries' application for comprehensive credit and loans from banks. It details the credit amounts, terms, purposes, and approvals from the board of directors, independent directors, and the supervisory board. The content focuses on financing activities, including credit applications and loan purposes, without presenting financial statements or earnings data. The document length is 4298 characters, which is relatively short and reads as an announcement rather than a full financial report. There is no indication of it being an earnings release, annual report, or other financial report type. The primary subject is financing updates related to credit and loan applications. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-11-21 Chinese
独立董事关于第五届董事会第三次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from independent directors regarding a board meeting decision about the company and its subsidiaries applying for comprehensive credit and loans from banks. It references compliance with regulatory rules and company bylaws, and it expresses approval of financing activities. The content focuses on board-level approval and independent director opinions related to financing but does not contain financial statements or detailed financial results. The document length is short (579 characters), and it is a formal opinion related to financing activities. This fits best under Capital/Financing Update (CAP) as it concerns updates on company financing activities and credit applications.
2022-11-21 Chinese
第五届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Yunnan Watson Biotechnology Co., Ltd. It details the approval of credit facilities and loans from banks, including amounts, terms, and authorization for financial departments to finalize contracts. The document includes voting results and mentions independent directors' opinions. There is no financial statement or detailed financial report content, but rather a corporate governance decision related to financing. This fits the category of Board/Management Information (MANG), as it announces decisions made by the board regarding financing approvals, not the financing update itself or a full financial report.
2022-11-21 Chinese
第五届监事会第三次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the company's and its subsidiaries' applications for comprehensive credit facilities and loans from banks. It includes details about the meeting date, participants, voting results, and the purpose of the credit facilities. There are no financial statements or detailed financial performance data presented. The document is an official announcement of a board decision related to financing activities but does not itself constitute a full financial report or detailed capital update. Given the content focuses on financing approvals and credit applications, it fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2022-11-21 Chinese
关于新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）获得临床试验伦理快速审查批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the approval of a clinical trial ethics rapid review for a new mRNA vaccine. It contains no financial data, no report or presentation, and is not related to shareholder meetings, financial results, or regulatory certifications. It is a regulatory announcement about clinical trial progress and approvals. The document length is short (935 characters), and it is an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2022-11-15 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.